Statements (33)
| Predicate | Object |
|---|---|
| gptkbp:instanceOf |
opioid
|
| gptkbp:approvedBy |
1926
|
| gptkbp:ATCCode |
N02AA03
|
| gptkbp:brand |
gptkb:hydromorphone
|
| gptkbp:chemicalClass |
semi-synthetic opioid
|
| gptkbp:contraindication |
acute or severe bronchial asthma
severe respiratory depression known hypersensitivity to hydromorphone |
| gptkbp:controlledSubstanceSchedule |
gptkb:Schedule_II_(US)
|
| gptkbp:eliminationHalfLife |
2-3 hours
|
| gptkbp:excretion |
urine
|
| gptkbp:form |
gptkb:tablet
oral solution injectable solution suppository |
| https://www.w3.org/2000/01/rdf-schema#label |
Dilaudid
|
| gptkbp:legalStatus |
prescription only
|
| gptkbp:manufacturer |
gptkb:Purdue_Pharma
|
| gptkbp:metabolism |
liver
|
| gptkbp:pregnancyCategory |
C (US)
|
| gptkbp:riskFactor |
addiction
overdose |
| gptkbp:routeOfAdministration |
oral
intramuscular subcutaneous intravenous |
| gptkbp:sideEffect |
nausea
constipation drowsiness respiratory depression |
| gptkbp:usedFor |
pain management
|
| gptkbp:bfsParent |
gptkb:Purdue_Pharma
|
| gptkbp:bfsLayer |
6
|